BAYER AG NA O.N.
Commented by Armin Schulz on November 20th, 2024 | 07:00 CET
Evotec, Nyxoah, Bayer – A lot of excitement in the healthcare industry
The healthcare sector is currently abuzz with activity. Evotec is the focus of a potential takeover by the US company Halozyme, which has caused the shares of the German biotech company to skyrocket. At the same time, the Belgian medical technology company Nyxoah expects to receive FDA approval soon for its Genio system for the treatment of sleep apnea, which would pave the way for its market entry in the US. Bayer, on the other hand, disappointed with its latest quarterly figures, which showed a significant decline in revenue and EBITDA, leading to a slide in its share price. We take a closer look at these three companies.
Read
Commented by Juliane Zielonka on November 14th, 2024 | 07:45 CET
Daimler Truck, dynaCERT, Bayer AG: Contrasts in Q3: Established companies under pressure, newcomers with breakthroughs
Established DAX corporations such as Bayer AG and Daimler Truck, a Mercedes-Benz Group company, are facing a headwind in the third quarter of 2024. However, the Canadian cleantech specialist dynaCERT is on the verge of its commercial breakthrough. The Leverkusen-based Bayer Group has to revise its forecast downwards. The agriculture business, in particular, is a cause for concern, while the pharmaceuticals division is scoring points with new drugs. At Daimler Truck, strong business in North America is stabilizing the balance sheet, while business in Europe is under pressure. dynaCERT, on the other hand, has received the valuable Verra certification for its hydrogen technology for diesel optimization after twenty years of development work. Investors finally have a viable hydrogen use case for logistics.
Read
Commented by André Will-Laudien on November 13th, 2024 | 07:30 CET
Gold correction - Now is the time to take advantage of the lows! Takeover rumors at Evotec, Desert Gold, Bayer and SMCI
The re-election of Donald Trump as US President had varying effects on the capital markets. The US dollar gained against all currencies, while the hot topic Bitcoin reached new all-time highs of over USD 90,000. The enormous influx of funds into the US stock markets initially slowed down other exchanges. At the same time, the previously sought-after precious metals corrected sharply, putting pressure on mining stocks again. The first shockwaves have now been absorbed, and attention is turning to the real political issues that the White House will now push forward. Defense, industry, and security are in the spotlight, while biotech and green tech remain sidelined. There are some interesting special movements that we will examine here.
Read
Commented by Armin Schulz on November 12th, 2024 | 07:00 CET
Bayer, BioNxt Solutions, Novo Nordisk – Opportunities in the healthcare industry
In a market characterized by technological breakthroughs and the growing demand for innovative therapies, companies such as Bayer, BioNxt Solutions and Novo Nordisk offer exciting investment opportunities. While Bayer, a global pharmaceutical giant with a broad product portfolio, promises stability and long-term growth, BioNxt Solutions relies on highly specialized biotechnological innovations with disruptive potential. Novo Nordisk, a leading player in diabetes and metabolic disorders, is benefiting from the growing demand for solutions for chronic diseases. For investors looking to capitalize on trends in the healthcare industry, these three companies could make all the difference.
Read
Commented by Juliane Zielonka on November 7th, 2024 | 07:00 CET
Vidac Pharma, BioNTech, Bayer - Billion-Dollar Gene Therapy Market Attracts Investors
Two trends are emerging in the pharmaceutical industry: personalized medicine, which tailors therapies to the genetic profile of individual patients, and the development of highly specific active ingredients that target biological mechanisms. Vidac Pharma is one of the companies focusing on these targeted therapies and recently received a groundbreaking US patent for its innovative approach to normalizing cancer cell metabolism - a concept known as the "Warburg effect reversal." BioNTech is driving its transformation from COVID-19 vaccine producer to cancer specialist, with promising Phase II trials underway for treatments targeting lung and breast cancers. Bayer, meanwhile, is under pressure due to disappointing sales of its partner Regeneron's eye drug Eylea® – the second most important product in the portfolio, which has to hold its own against growing competition. Where is an investment worthwhile?
Read
Commented by André Will-Laudien on November 6th, 2024 | 08:00 CET
US election and the biotech sector – A hot November is on the cards! BioNTech, Pfizer, Nyxoah, Bayer or Evotec?
With anticipation building for both the Q3 earnings season and the US election results, the markets are in a wait-and-see mode. Democrat frontrunner Kamala Harris is said to be committed to continuing the successful policies of her predecessor Joe Biden. Of course, science, research and climate protection are in the spotlight. Her rival, Donald Trump, is said to be more concerned with strengthening the traditional economy, where automotive engineering, the defense industry and security companies come to the fore. Additionally, markets are looking to central banks for cues, as lower interest rates would be a boon for the biotech sector. Here are some investment ideas for dynamic investors in this promising climate.
Read
Commented by Juliane Zielonka on October 30th, 2024 | 07:45 CET
Nyxoah, Bayer and Palantir - The billion-dollar precision medicine market: Why investors are now taking notice
Precision medicine is revolutionizing global healthcare: Experts predict that this future market will reach over USD 175 billion by 2028, driven by the growing demand for individualized treatment methods. Three companies stand out in particular: Belgian medical technology company Nyxoah is developing a mask-free therapy for the 936 million people worldwide with sleep apnea with its Genio system, while Bayer AG is revolutionizing fertility treatment through real-time hormone monitoring through its partnership with Impli. With its foundry platform, technology leader Palantir enables pharmaceutical giant Sanofi to analyze the health data of over 300 million patients. These patient-centered innovations not only promise better treatment outcomes for millions of people but also present investors access to one of the most dynamic growth markets in the healthcare sector.
Read
Commented by André Will-Laudien on October 24th, 2024 | 07:30 CEST
Biotech – Are takeovers looming amidst curious prices? Evotec, Bayer, Vidac Pharma and BioNTech in the spotlight
The biotech sector is once again in the spotlight. Since the acquisition of MorphoSys at the beginning of the year, the speculation carousel is turning again. Is Evotec next, or maybe Vidac Pharma? The Hamburg-based drug specialist came under fire from short-sellers after the resignation of long-standing CEO Lanthaler, who had shorted over 4% of the capital by mid-September. However, the price stubbornly held above the EUR 5 mark, and yesterday saw a 10% rise to EUR 6.60. What is behind this? Last week, it was Vidac Pharma that surged 300% from a standing start with enormous trading volumes. The thought processes of market participants are evident: interest rates are falling, making refinancing attractive again for upcoming financial investors. We shed light on the key players.
Read
Commented by Fabian Lorenz on October 23rd, 2024 | 07:30 CEST
More than 100% upside potential! Bayer, Plug Power and 123fahrschule – Which stock is convincing?
Analysts see more than a 100% upside potential in the 123fahrschule stock. The exciting second-line stock wants to make driver education more modern and efficient and is getting support from politicians. Accordingly, sales and profits should rise sharply. Plug Power can also show rising sales, but like industry colleague Nel, the Americans are unable to get a grip on their losses. Will the quarterly figures turn things around? Bayer shareholders have been waiting for a turnaround for quite some time. But analysts also expect falling profits in the coming quarterly report. Is there still potential for a 40% increase in the DAX share?
Read
Commented by Juliane Zielonka on October 17th, 2024 | 07:15 CEST
Saturn Oil + Gas, Bayer, Siemens Energy: Three companies for balance in volatile times
In uncertain times like these, a balanced portfolio is crucial for every investor. Also, in view of the upcoming US election, diversification across different sectors is worthwhile to offset fluctuations in the portfolio. Saturn Oil & Gas relies on a combination of share buybacks and targeted acquisitions. With an adjusted EBITDA of approximately CAD 400 million, the Company is demonstrating its financial strength and potential for further growth. By applying for approval of a drug for menopausal symptoms to the European Medicines Agency (EMA), Bayer AG is targeting a global market that is expected to grow to a remarkable USD 26.97 billion by 2031. Global player Siemens Energy is focusing on the reorganization of its wind business and its participation in offshore wind energy projects. The early contract extension of CEO Christian Bruch until 2030 underlines the confidence in the current course. Today, we have three companies in focus.
Read